Advertisement
Research Article

Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis

  • Rebecca Craig-Schapiro,

    Affiliation: Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, United States of America

    X
  • Max Kuhn,

    Affiliations: Neuroscience Research Unit, Pfizer Global Research and Development, Groton, Connecticut, United States of America, Neuroscience Research Unit, Pfizer Global Research and Development, St. Louis, Missouri, United States of America

    X
  • Chengjie Xiong,

    Affiliations: The Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, United States of America, Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri, United States of America

    X
  • Eve H. Pickering,

    Affiliations: Neuroscience Research Unit, Pfizer Global Research and Development, Groton, Connecticut, United States of America, Neuroscience Research Unit, Pfizer Global Research and Development, St. Louis, Missouri, United States of America

    X
  • Jingxia Liu,

    Affiliation: Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri, United States of America

    X
  • Thomas P. Misko,

    Affiliations: Neuroscience Research Unit, Pfizer Global Research and Development, Groton, Connecticut, United States of America, Neuroscience Research Unit, Pfizer Global Research and Development, St. Louis, Missouri, United States of America

    X
  • Richard J. Perrin,

    Affiliations: The Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, United States of America, Division of Neuropathology, Washington University School of Medicine, St. Louis, Missouri, United States of America, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America

    X
  • Kelly R. Bales,

    Affiliations: Neuroscience Research Unit, Pfizer Global Research and Development, Groton, Connecticut, United States of America, Neuroscience Research Unit, Pfizer Global Research and Development, St. Louis, Missouri, United States of America

    X
  • Holly Soares,

    Affiliations: Neuroscience Research Unit, Pfizer Global Research and Development, Groton, Connecticut, United States of America, Neuroscience Research Unit, Pfizer Global Research and Development, St. Louis, Missouri, United States of America

    X
  • Anne M. Fagan,

    Affiliations: Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, United States of America, The Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, United States of America, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, Missouri, United States of America

    X
  • David M. Holtzman mail

    holtzman@neuro.wustl.edu

    Affiliations: Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, United States of America, The Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, United States of America, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, Missouri, United States of America

    X
  • Published: April 19, 2011
  • DOI: 10.1371/journal.pone.0018850

Viewed info

Cited info

Saved info

Discussed info

Questions or concerns about usage data? Please let us know.